{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T21:42:17Z","timestamp":1791495737175,"version":"4.3.4"},"reference-count":49,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1097\/fpc.0000000000000306","type":"journal-article","created":{"date-parts":[[2017,10,31]],"date-time":"2017-10-31T13:21:35Z","timestamp":1509456095000},"page":"429-437","source":"Crossref","is-referenced-by-count":96,"title":["Dapsone-induced severe cutaneous adverse drug reactions are strongly linked with HLA-B*13"],"prefix":"10.1097","volume":"27","author":[{"given":"Therdpong","family":"Tempark","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patompong","family":"Satapornpong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawinee","family":"Rerknimitr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nontaya","family":"Nakkam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niwat","family":"Saksit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Penpun","family":"Wattanakrai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thawinee","family":"Jantararoungtong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Napatrupron","family":"Koomdee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajanee","family":"Mahakkanukrauh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wichittra","family":"Tassaneeyakul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumitra","family":"Suttisai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jirawat","family":"Pratoomwun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jettanong","family":"Klaewsongkram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ticha","family":"Rerkpattanapipat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chonlaphat","family":"Sukasem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-1-20210213","doi-asserted-by":"crossref","first-page":"17","DOI":"10.12788\/j.sder.0059","article-title":"Severe cutaneous adverse reactions impact of immunology genetics and pharmacology","volume":"33","author":"Harp","year":"2014","journal-title":"Semin Cutan Med Surg"},{"key":"R2-1-20210213","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1590\/S0104-42302012000300003","article-title":"Severe cutaneous adverse reactions (SCAR) syndromes","volume":"58","author":"Marotti","year":"2012","journal-title":"Rev Assoc Med Bras"},{"key":"R3-1-20210213","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1346-8138.2010.01196.x","article-title":"Pharmacogenetics of cutaneous adverse drug reactions","volume":"38","author":"Aihara","year":"2011","journal-title":"J Dermatol"},{"key":"R4-1-20210213","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1590\/S0365-05962012000300013","article-title":"Drug reaction with Eosinophilia and Systemic Symptoms (DRESS)\/Drug-induced Hypersensitivity Syndrome (DIHS): a review of current concepts","volume":"87","author":"Criado","year":"2012","journal-title":"An Bras Dermatol"},{"key":"R5-1-20210213","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1111\/j.1365-2133.2006.07284.x","article-title":"Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist","volume":"155","author":"Peyriere","year":"2006","journal-title":"Br J Dermatol"},{"key":"R6-1-20210213","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.amjmed.2011.01.017","article-title":"The DRESS syndrome: a literature review","volume":"124","author":"Cacoub","year":"2011","journal-title":"Am J Med"},{"key":"R7-1-20210213","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1365-2230.2010.03967.x","article-title":"Drug reaction with eosinophilia and systemic symptoms (DRESS): a clinical update and review of current thinking","volume":"36","author":"Walsh","year":"2011","journal-title":"Clin Exp Dermatol"},{"key":"R8-1-20210213","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1067\/mjd.2001.114733","article-title":"Dapsone and sulfones in dermatology: overview and update","volume":"45","author":"Zhu","year":"2001","journal-title":"J Am Acad Dermatol"},{"key":"R9-1-20210213","first-page":"57","article-title":"Increase in the incidence of dapsone hypersensitivity syndrome an appraisal","volume":"72","author":"Rao","year":"2001","journal-title":"Lepr Rev"},{"key":"R10-1-20210213","first-page":"266","article-title":"Dapsone syndrome in Vanuatu: a high incidence during multidrug treatment (MDT) of leprosy","volume":"95","author":"Reeve","year":"1992","journal-title":"J Trop Med Hyg"},{"key":"R11-1-20210213","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/S0190-9622(96)90667-2","article-title":"Dapsone hypersensitivity syndrome","volume":"35","author":"Prussick","year":"1996","journal-title":"J Am Acad Dermatol"},{"key":"R12-1-20210213","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.alit.2016.04.001","article-title":"Drug-induced hypersensitivity syndrome\/drug reaction with eosinophilia and systemic symptoms (DIHS\/DRESS): 11 years retrospective study in Thailand","volume":"65","author":"Hiransuthikul","year":"2016","journal-title":"Allergol Int"},{"key":"R13-1-20210213","first-page":"111","article-title":"Pharmacogenomics of drug-induced hypersensitivity reactions: challenges, opportunities and clinical implementation","volume":"32","author":"Sukasem","year":"2014","journal-title":"Asian Pac J Allergy Immunol"},{"key":"R14-1-20210213","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1073\/pnas.0409500102","article-title":"HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol","volume":"102","author":"Hung","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"R15-1-20210213","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S0140-6736(02)07873-X","article-title":"Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir","volume":"359","author":"Mallal","year":"2002","journal-title":"Lancet"},{"key":"R16-1-20210213","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.2217\/pgs.12.108","article-title":"HLA and pharmacogenetics of drug hypersensitivity","volume":"13","author":"Pavlos","year":"2012","journal-title":"Pharmacogenomics"},{"key":"R17-1-20210213","doi-asserted-by":"crossref","first-page":"349","DOI":"10.2217\/pgs.09.162","article-title":"Common risk allele in aromatic antiepileptic-drug induced Stevens\u2013Johnson syndrome and toxic epidermal necrolysis in Han Chinese","volume":"11","author":"Hung","year":"2010","journal-title":"Pharmacogenomics"},{"key":"R18-1-20210213","doi-asserted-by":"crossref","first-page":"AB115","DOI":"10.1016\/j.jaci.2014.12.1309","article-title":"The association of HLA-B* 5101 and phenobarbital-induced severe cutaneous adverse drug reactions in Thai children","volume":"135","author":"Likkasittipan","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"R19-1-20210213","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1097\/FPC.0000000000000153","article-title":"Candidate HLA genes for prediction of co-trimoxazole-induced severe cutaneous reactions","volume":"25","author":"Kongpan","year":"2015","journal-title":"Pharmacogenet Genomics"},{"key":"R20-1-20210213","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/FPC.0000000000000211","article-title":"Associations between HLA class I and cytochrome P450 2C9 genetic polymorphisms and phenytoin-related severe cutaneous adverse reactions in a Thai population","volume":"26","author":"Tassaneeyakul","year":"2016","journal-title":"Pharmacogenet Genomics"},{"key":"R21-1-20210213","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.1038\/jid.2013.192","article-title":"Association between HLA-B*1301 and dapsone-induced hypersensitivity reactions among leprosy patients in China","volume":"133","author":"Wang","year":"2013","journal-title":"J Invest Dermatol"},{"key":"R22-1-20210213","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1056\/NEJMoa1213096","article-title":"HLA-B*13:01 and the dapsone hypersensitivity syndrome","volume":"369","author":"Zhang","year":"2013","journal-title":"N Engl J Med"},{"key":"R23-1-20210213","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S0966-842X(98)01240-2","article-title":"Human leukocyte antigens in tuberculosis and leprosy","volume":"6","author":"Meyer","year":"1998","journal-title":"Trends Microbiol"},{"key":"R24-1-20210213","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1365-4362.1988.tb03218.x","article-title":"The HLA association of lepromatous leprosy and borderline lepromatous leprosy in Turkey. A preliminary study","volume":"27","author":"Cem Mat","year":"1988","journal-title":"Int J Dermatol"},{"key":"R25-1-20210213","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/j.1399-0039.1985.tb00966.x","article-title":"Leprosy associated with HLA-DR2 and DQw1 in the population of northern Thailand","volume":"26","author":"Schauf","year":"1985","journal-title":"Tissue Antigens"},{"key":"R26-1-20210213","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/j.1399-0039.1987.tb01567.x","article-title":"HLA and leprosy in Koreans","volume":"29","author":"Kim","year":"1987","journal-title":"Tissue Antigens"},{"key":"R27-1-20210213","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/sj.gene.6364390","article-title":"HLA-DRB1*04 and DRB1*10 are associated with resistance and susceptibility, respectively, in Brazilian and Vietnamese leprosy patients","volume":"8","author":"Vanderborght","year":"2007","journal-title":"Genes Immun"},{"key":"R28-1-20210213","first-page":"49","article-title":"Human leukocyte antigens in forms of leprosy among Japanese patients","volume":"68","author":"Joko","year":"2000","journal-title":"Int J Lepr Other Mycobact Dis"},{"key":"R29-1-20210213","first-page":"241","article-title":"Variants of HLA-DR2\/DR51 group haplotypes and susceptibility to tuberculoid leprosy and pulmonary tuberculosis in Asian Indians","volume":"63","author":"Mehra","year":"1995","journal-title":"Int J Lepr Other Mycobact Dis"},{"key":"R30-1-20210213","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.humimm.2010.03.007","article-title":"Association of HLA-DRB1*0405 with resistance to multibacillary leprosy in Taiwanese","volume":"71","author":"Hsieh","year":"2010","journal-title":"Hum Immunol"},{"key":"R31-1-20210213","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1001\/archderm.1993.01680220104023","article-title":"Clinical classification of cases of toxic epidermal necrolysis, Stevens\u2013Johnson syndrome, and erythema multiforme","volume":"129","author":"Bastuji-Garin","year":"1993","journal-title":"Arch Dermatol"},{"key":"R32-1-20210213","first-page":"203","article-title":"Severe cutaneous adverse reactions to drugs (SCAR): definitions, diagnostic criteria, genetic predisposition","volume":"27","author":"Roujeau","year":"2009","journal-title":"Article in Dermatologica Sinica"},{"key":"R33-1-20210213","first-page":"1","article-title":"HLA-B allele and haplotype diversity among Thai patients identified by PCR-SSOP: evidence for high risk of drug-induced hypersensitivity","volume":"478","author":"Puangpetch","year":"2015","journal-title":"Front Genet"},{"key":"R34-1-20210213","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1146\/annurev-pharmtox-010611-134701","article-title":"Drug hypersensitivity and human leukocyte antigens of the major histocompatibility complex","volume":"52","author":"Bharadwaj","year":"2012","journal-title":"J Annu Rev Pharmacol Toxicol"},{"key":"R35-1-20210213","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1146\/annurev.immunol.23.021704.115658","article-title":"How TCRs bind MHCs, peptides, and coreceptors","volume":"24","author":"Rudolph","year":"2006","journal-title":"Annu Rev Immunol"},{"key":"R36-1-20210213","first-page":"370","article-title":"Dapsone hypersensitivity syndrome among leprosy patients in China","volume":"83","author":"Tian","year":"2012","journal-title":"Lept Rev"},{"key":"R37-1-20210213","doi-asserted-by":"crossref","first-page":"68","DOI":"10.5415\/apallergy.2015.5.2.68","article-title":"HLA-B*1502 and carbamazepine-induced severe cutaneous adverse drug reactions in Vietnamese","volume":"5","author":"Nguyen","year":"2015","journal-title":"Asia Pac Allergy"},{"key":"R38-1-20210213","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/j.1365-4632.2010.04745.x","article-title":"Association of HLA-B*1502 allele with carbamazepine-induced toxic epidermal necrolysis and Stevens\u2013Johnson syndrome in the multi-ethnic Malaysian population","volume":"50","author":"Chang","year":"2011","journal-title":"Int J Dermatol"},{"key":"R39-1-20210213","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.2217\/14622416.9.10.1543","article-title":"Carbamazepine, HLA-B*1502 and risk of Stevens\u2013Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations","volume":"9","author":"Ferrell","year":"2008","journal-title":"Pharmacogenomics"},{"key":"R40-1-20210213","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1093\/hmg\/ddq537","article-title":"Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population","volume":"20","author":"Ozeki","year":"2011","journal-title":"Hum Mol Genet"},{"key":"R41-1-20210213","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1056\/NEJMoa1013297","article-title":"HLA-A*31-01 and carbamazepine-induced hypersensitivity reactions in Europeans","volume":"364","author":"McCormack","year":"2011","journal-title":"N Engl J Med"},{"key":"R43-1-20210213","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s13601-015-0073-8","article-title":"Pathogenesis and diagnosis of delayed-type drug hypersensitivity reactions, from bedside to bench and back","volume":"5","author":"Schrijvers","year":"2015","journal-title":"Clin Transl Allergy"},{"key":"R44-1-20210213","doi-asserted-by":"crossref","first-page":"118","DOI":"10.3349\/ymj.2016.57.1.118","article-title":"HLA allele frequencies in 5802 Koreans: varied allele types associated with SJS\/TEN according to culprit drugs","volume":"57","author":"Park","year":"2016","journal-title":"Yonsei Med J"},{"key":"R45-1-20210213","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1007\/s008940050047","article-title":"Molecular modeling study on dapsone and sulfonamides comparing structures and properties with respect to anti-leprosy activity","volume":"3","author":"Scior","year":"1997","journal-title":"J Mol Model"},{"key":"R46-1-20210213","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1097\/00007611-200194080-00014","article-title":"Practical issues in the management of hypersensitivity reactions: sulfonamides","volume":"94","author":"Tilles","year":"2001","journal-title":"South Med J"},{"key":"R47-1-20210213","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1001\/archderm.1981.01650010044023","article-title":"Dapsone hypersensitivity: the sulfone syndrome revisited","volume":"117","author":"Tomecki","year":"1981","journal-title":"Arch Dermatol"},{"key":"R48-1-20210213","doi-asserted-by":"crossref","first-page":"115","DOI":"10.4103\/0022-3859.81865","article-title":"Drug-induced Stevens\u2013Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS-TEN overlap: a multicentric retrospective study","volume":"57","author":"Barvaliya","year":"2011","journal-title":"J Postgrad Med"},{"key":"R49-1-20210213","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1056\/NEJM199411103311906","article-title":"Severe adverse cutaneous reactions to drugs","volume":"331","author":"Roujeau","year":"1994","journal-title":"N Engl J Med"},{"key":"R50-1-20210213","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/FPC.0b013e3282f3ef9c","article-title":"A European study of HLA-B in Stevens\u2013Johnson syndrome and toxic epidermal necrolysis related to five high risk drugs","volume":"18","author":"Lonjou","year":"2008","journal-title":"Pharmacogenet Genomics"}],"container-title":["Pharmacogenetics and Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FPC.0000000000000306","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T20:24:04Z","timestamp":1620937444000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01213011-201712000-00001"}},"subtitle":["01 allele in the Thai population"],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":49,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/fpc.0000000000000306","relation":{},"ISSN":["1744-6872"],"issn-type":[{"value":"1744-6872","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]}}}